The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance
- 1 October 2012
- journal article
- review article
- Published by Elsevier in Current Opinion in Virology
- Vol. 2 (5) , 644-650
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research (CIHR)
This publication has 48 references indexed in Scilit:
- Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistanceProceedings of the National Academy of Sciences, 2011
- Comparative Study of the Genetic Barriers and Pathways towards Resistance of Selective Inhibitors of Hepatitis C Virus ReplicationAntimicrobial Agents and Chemotherapy, 2011
- Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon SystemAntimicrobial Agents and Chemotherapy, 2010
- APOBEC3G Contributes to HIV-1 Variation through Sublethal MutagenesisJournal of Virology, 2010
- Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C VirusScience Translational Medicine, 2010
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Template Usage Is Responsible for the Preferential Acquisition of the K65R Reverse Transcriptase Mutation in Subtype C Variants of Human Immunodeficiency Virus Type 1Journal of Virology, 2009
- Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479Antimicrobial Agents and Chemotherapy, 2008
- Cytidine deamination induced HIV-1 drug resistanceProceedings of the National Academy of Sciences, 2008
- General Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2′-Modified Nucleotide AnaloguesAntimicrobial Agents and Chemotherapy, 2006